TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 4 of the 33 sources its claims cite were checked for support.
Abstract
Cellular mechanisms that mediate steatohepatitis, an increasingly prevalent condition in the Western world for which no therapies are available, are poorly understood. Despite the fact that its synthetic agonists induce fatty liver, the liver X receptor (LXR) transcription factor remains a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory activities. Here we show that tetratricopeptide repeat domain protein 39B (Ttc39b, C9orf52) (T39), a high-density lipoprotein gene discovered in human genome-wide association studies, promotes the ubiquitination and degradation of LXR. Chow-fed mice lacking T39 (T39−/−) display increased high-density lipoprotein cholesterol levels associated with increased enterocyte ATP-binding cassette transporter A1 (Abca1) expression and increased LXR protein without change in LXR messenger RNA. When challenged with a high fat/high cholesterol/bile salt diet, T39−/− mice or mice with hepatocyte-specific T39 deficiency show increased hepatic LXR protein and target gene expression, and unexpectedly protection from steatohepatitis and death. Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr−/−T39−/−) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprotein, and reduced atherosclerosis. In addition to increasing hepatic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic sterol regulatory element-binding protein 1 (SREBP-1, ADD1) processing. This is explained by an increase in microsomal phospholipids containing polyunsaturated fatty acids, linked to an LXRα-dependent increase in expression of enzymes mediating phosphatidylcholine biosynthesis and incorporation of polyunsaturated fatty acids into phospholipids. The preservation of endogenous LXR protein activates a beneficial profile of gene expression that promotes cholesterol removal and inhibits lipogenesis. T39 inhibition could be an effective strategy for reducing both steatohepatitis and atherosclerosis.
Overview
CoChat Summary
TL;DR
TTC39B (T39) promotes ubiquitination and degradation of LXR; T39 deficiency stabilizes LXR protein and protects mice from both steatohepatitis and atherosclerosis. The mechanism couples increased cholesterol removal with inhibited SREBP-1 processing and lipogenesis.
Key findings
- T39 deficiency increased HDL cholesterol by ∼22% in chow-fed mice and by 42% after HF/HC/BS diet, with a 45% increase in ApoA-1; this was linked to increased intestinal Abca1 and post-transcriptional LXR protein induction.
- In HF/HC/BS-fed T39−/− mice, there was a 4-fold reduction in mortality (p<0.05), decreased ALT, less hepatic TG and cholesteryl ester accumulation, fewer inflammatory foci, less ballooning, and less fibrosis; protection was due to hepatic T39 deficiency and was LXRα-dependent.
- T39 deficiency inhibited hepatic SREBP-1 processing and reduced lipogenic gene expression and TG synthesis, associated with LXRα-dependent induction of Insig2a, Pcyt1a, Cept1, and Lpcat3, a 30% increase in microsomal phosphatidylcholine, and increased PUFA content in phospholipids.
- In WTD-fed Ldlr−/−T39−/− mice, T39 deficiency decreased fatty liver, increased HDL, decreased LDL, and reduced atherosclerotic lesion area and lesion complexity.
Methods
- Mouse models included whole-body T39−/−, tissue-specific Villin-Cre and Albumin-Cre T39fl/fl, Ldlr−/−T39−/−, and Lxrα−/−T39−/− mice; both sexes, 10–20 weeks old, fed chow, HF/HC/BS diet (7.5% cocoa butter, 1.25% cholesterol, 0.5% sodium cholate), or WTD (21% milk fat, 0.15% cholesterol), with blinded measurements.
- Analyses included lipoprotein/cholesterol/TG assays, Western blotting, gene expression, [3H]cholesterol secretion from enterocytes, NASH histological grading, dietary cholesterol absorption, GC-MS sterol/oxysterol measurement, in vivo lipogenesis, lipidomics, atherosclerosis quantification, ChIP, co-immunoprecipitation, GW3965-affinity LXR pulldown, and LXRα turnover assays.
- Statistics used mean ± SEM, two-tailed Student t-test or two-way ANOVA with Bonferroni post hoc, p<0.05 significance, and Grubbs’ test for outliers.
Limitations
- The paper does not state limitations explicitly. Evident from the text: all functional and therapeutic conclusions come from mouse models and cell culture, with no human interventional or clinical validation.
- Several mechanistic links are proposed rather than fully established; the text notes “there must be a separate more physiologically relevant mechanism regulating SREBP-1 maturation” and that increased PC synthesis/PUFA incorporation “may be a major factor” inhibiting NAFLD.
- No pharmacological T39 inhibitor was tested in vivo; the therapeutic implication that “T39 inhibition could be an effective strategy” remains untested in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 0 Not valid · 25 Not checked · 128 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is longstanding evidence that the intestine makes a substantial contribution to the production of HDL5,6.”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Supportedcites [5] Brunham LR Intestinal ABCA1 directly contributes to HDL biogenesis in vivo The Journal of clinical investigation 116 1052 1062 10.1172/JCI27352 2006 16543947 PMC1401485 source
The Abstract and Discussion of Brunham et al. (2006) state that intestinal ABCA1 contributes approximately 30% of the steady-state plasma HDL cholesterol pool in mice and 'establish a critical role for intestinal ABCA1 in plasma HDL biogenesis in vivo'; the Figure 7 legend likewise concludes the intestine is 'crucially involved in the maintenance of plasma HDL levels'. The Introduction adds that the intestine contributes roughly 50% of total plasma apoA-I and reviews earlier (Roheim 1966; Green 1978; Forester 1983) evidence of intestinal HDL secretion, consistent with the citing sentence's 'longstanding evidence'. The quantitative contribution is bounded by the mouse model used, which the citing sentence does not specify, but the attributed point — a substantial intestinal contribution to HDL production — is stated in our copy. (LLM, conf=0.85)
- Not checked yetcites [6] Wu AL Windmueller HG Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat The Journal of biological chemistry 254 7316 7322 1979 457683 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We also observed induction of other intestinal LXR target genes including Inducible degrader of LDLR (Idol, Mylip1)8 (ED Fig 2d).”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Supportedcites [8] Zelcer N Hong C Boyadjian R Tontonoz P LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Science 325 100 104 2009 19520913 PMC2777523 source
Passage 3 (Results) identifies the LXR target gene the citing sentence credits to ref 8: 'LXR agonists induced Idol expression... Treatment of mice with GW3965 induced expression of Idol in multiple tissues, including spleen, intestine and adrenals (Fig. 2B)', and gives exactly the nomenclature the claim uses — 'variably referred to as Mir and Mylip... we propose... be renamed Idol (for Inducible Degrader of the LDLR)'. Passage 1 repeats the intestinal induction, and passage 2 confirms the intestine as a tissue where LXR-Idol signalling is prominent. The citing authors' own observation in T39-/- mice is theirs; the citation is offered only to identify Idol/Mylip1 as an intestinal LXR target gene, which our copy states directly. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The reduction in TG synthesis was accompanied by decreased expression of many lipogenic genes, including Scd1, Elovl5, Acetyl-CoA carboxylase α (Accα), Glycerol-3-phosphate acyltransferase (Gpat1, Gpam), and Glucose-6-phosphate dehydrogenase (G6pd), as well as Patatin-like phospholipase domain-containing protein 3 (Pnpla3, Adiponutrin), which is an SREBP-1 target implicated in human hepatic steato”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
What the sources say
- Partly supportedcites [17] Huang Y A feed-forward loop amplifies nutritional regulation of PNPLA3 Proc Natl Acad Sci U S A 107 7892 7897 2010 20385813 PMC2867902 sourceExperimental — accuracy not yet measured
Our copy supports only the trailing characterization of Pnpla3: the Transcriptional Regulation section (and Fig. 2 legend) shows PNPLA3/adiponutrin is a direct SREBP-1c target (up-regulated ~90-fold by refeeding, blocked in Scap-/- and SREBP-1c-/- mice, SREBP-1 chromatin peak in intron 1), and the opening paragraph credits the I148M variant with conferring susceptibility to hepatic TG deposition. The main attributed observation is not in this paper: no passage mentions Scd1, Elovl5, Accα, Gpat1 or G6pd (searched those gene names plus 'lipogenic gene expression'), and the only experiment here that reduces TG synthesis — triacsin C in oleate-treated HuH-7 cells (Posttranslational Regulation of PNPLA3 by Fatty Acids; reiterated in the Abstract and Discussion) — reports the opposite for PNPLA3, namely that the fatty-acid-induced increase in PNPLA3 persisted despite blocked TG synthesis, with oleate raising protein mass without any change in PNPLA3 mRNA. So the gene panel and the coupling of reduced TG synthesis to decreased Pnpla3 expression are not supported by this source. (LLM, conf=0.78)
- Could not verifycites [18] Romeo S Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 1461 1465 2008 18820647 PMC2597056 sourceExperimental — accuracy not yet measured
Our copy of Romeo et al. (2008) is a human genetic association study (Dallas Heart Study admixture mapping/resequencing plus ARIC replication); no passage reports suppressing hepatic TG synthesis or measures expression of Scd1, Elovl5, Accα, Gpat1 or G6pd — searches for 'lipogenic genes', 'SREBP-1', 'adiponutrin mRNA expression in mouse liver' returned only the discussion of nutritional regulation of PNPLA3 (Abstract, p. ~n/p: 'mRNA levels are low in the fasted state and increase dramatically with carbohydrate feeding', credited to refs 20 and 21, Baulande et al. 2001 and Lake et al. 2005). That passage addresses fasting/feeding regulation, not a reduction in TG synthesis, so it neither supports nor contradicts the attributed expression finding. The copy does support the separate point that PNPLA3-I148M is associated with increased hepatic fat content in humans (Abstract, Fig. 1b/Fig. 2b), but the expression claim itself is not addressed anywhere in our copy. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The livers of Albumin-Cre(+)T39fl/fl mice had less perisinusoidal and periportal fibrosis compared to the T39fl/fl and Villin-Cre(+)T39fl/fl mice (Fig 1g and ED Fig 4a,b)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in the mature form of SREBP-1 associated with T39 deficiency was LXRα-dependent (ED Fig 6b).”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims
Create a free account to see all 156 claims and to verify the 29 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“the decrease in [3H]-labelled TG observed in Figure 3D”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“PC, PE and phosphatidylserine PS species all had significantly increased PUFA content (Fig 3d,e,f)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Hepatic plant sterol content of WT, whole body T39 knockout, LXRα knockout, and LXRα T39 double knockout mice fed HF/HC/BS diet for 6 weeks”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 4 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 4 Lxrα-/-T39+/+, and 6 Lxrα-/-T39+/+.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“Liver cell injury was assigned a score from 0 to 2 as follows:”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“majority of hepatocytes are ballooned = 3.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“T39-/- mice challenged with 3 weeks of the HF/HC/BS diet had a 42% increase in HDL cholesterol levels (ED Fig 2a)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“(a) HDL-cholesterol of WT and whole body T39 knockout mice fed chow or HF/HC/BS diet for 4 weeks, n=4 per genotype for chow, 5 per genotype for HF/HC/BS diet.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Absorption of [14C]cholesterol administered by gavage to WT and whole body T39 knockout with/without LXRα along with Poloxamer-407 injection to inhibit peripheral lipoprotein catabolism”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 3 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 3 Lxrα-/-T39+/+, and 5 Lxrα-/-T39+/+.”
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 2×
“Genome-wide association studies have uncovered a plethora of novel genetic loci associated with alterations in plasma lipoprotein levels 2,3 that have potential to provide insights into metabolic diseases such as atherosclerosis and fatty liver.”
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979
Self-citationLXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732 · cited 1×
“Also, LPCAT3 activity ameliorates ER stress 10 , which affects SREBP-1 processing 24 .”
Cited by
Weeks, E. M., Ulirsch, J. C., Cheng, N. Y., Trippe, B. L., Fine, R. S., Miao, J., Patwardhan, T. A., Kanai, M., Nasser, J., Fulco, C. P., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01443-6 · Cited by 349
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Li, H., Yu, X.-H., Ou, X., Ouyang, X.-P., & Tang, C.-K. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101109 · Cited by 227
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D.-W., Zheng, X.-L., & Tang, C.-K. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 218
Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-05006-3 · Cited by 188
Varin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J.-F., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.001 · Cited by 138
Yu, X.-H., Deng, W., Chen, J., Xu, X., Liu, X.-X., Chen, L., Shi, M., Liu, Q.-X., Tao, M., & Ren, K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03263-6 · Cited by 120
Receptor-Mediated ER Export of Lipoproteins Controls Lipid Homeostasis in Mice and Humans
Wang, X., Wang, H., Xu, B., Huang, D., Nie, C., Pu, L., Zajac, G. J. M., Yan, H., Zhao, J., Shi, F., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.020 · Cited by 119
Rebholz, C., Krawczyk, M. J., & Lammert, F. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12935 · Cited by 107
HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Vitali, C., Khetarpal, S. A., & Rader, D. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0940-0 · Cited by 102
Self-citationCelastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma
Zhang, C.-J., Zhu, N., Long, J., Wu, H.-T., Wang, Y., Liu, B.-Y., Liao, D., & Li, Q. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00572-6 · Cited by 87
Fang, W., Huang, J., Li, S., & Lü, J. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737429 · Cited by 80
Kapuria, D., Takyar, V. K., Etzion, O., Surana, P., O'Keefe, J. H., & Koh, C. (2018) · Hepatology Communications · doi:10.1002/hep4.1199 · Cited by 66
Wang, W., Zhang, Z., Wu, Y., Wang, R.-Q., Chen, J., Chen, J., Zhang, Y., Chen, Y.-J., Geng, M., Xu, Z., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00195 · Cited by 66
The ubiquitous role of ubiquitination in lipid metabolism
Loix, M., Zelcer, N., Bogie, J. F. J., & Hendriks, J. J. A. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.001 · Cited by 62
Guo, X. H., Zhong, J., Zhao, Y., Fu, Y., Sun, L., Yuan, A., Liu, J., Chen, A. F., & Pu, J. (2024) · Circulation · doi:10.1161/circulationaha.123.065202 · Cited by 58
Liver X receptor: a potential target in the treatment of atherosclerosis
Savla, S. R., Prabhavalkar, K. S., & Bhatt, L. K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2117610 · Cited by 57
miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1
Guo, Y., Yu, J., Wang, C., Li, K., Liu, B., Du, Y., Xiao, F., Chen, S., & Guo, F. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0179 · Cited by 57
Li, Z., Votava, J. A., Zajac, G. J. M., Nguyen, J. N., Jaimes, F. L., Ly, S. M., Brinkman, J. A., Giorgi, M. D., Kaul, S., Green, C. L., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.015 · Cited by 48
CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation
Li, K., Zhang, J., Lyu, H., Yang, J., Wei, W., Wang, Y., Luo, H., Zhang, Y., Jiang, X. J., Yi, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202306827 · Cited by 47
Yang, B., Zhang, B., Cao, Z., Xu, X., Huo, Z., Zhang, P., Xiang, S., Zhao, Z., Lv, C., Meng, M., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0514-3 · Cited by 44
Cross-species data integration to prioritize causal genes in lipid metabolism
Votava, J. A., & Parks, B. W. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000742 · Cited by 41
Beyond the Foam Cell: The Role of LXRs in Preventing Atherogenesis
Rasheed, A., & Cummins, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082307 · Cited by 40
Ahi, E. P., Lecaudey, L. A., Ziegelbecker, A., Steiner, O., Goessler, W., & Sefc, K. M. (2020) · Biology Letters · doi:10.1098/rsbl.2020.0629 · Cited by 38
Bonelli, R., Jackson, V. E., Prasad, A., Munro, J. E., Farashi, S., Heeren, T. F. C., Pontikos, N., Scheppke, L., Friedlander, M., Egan, C. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01788-w · Cited by 38
Xie, J., Peng, L., wang, T., Yang, C., Chen, N., Feng, X., Wu, T., Xu, T., & Chen, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116684 · Cited by 38
Christensen, J. J., Ulven, S. M., Retterstøl, K., Narverud, I., Bogsrud, M. P., Henriksen, T., Bollerslev, J., Halvorsen, B. L., Aukrust, P., & Holven, K. B. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.021 · Cited by 37
Development of a Novel DNA Oligonucleotide Targeting Low-Density Lipoprotein Receptor
Wang, T., Rahimizadeh, K., & Veedu, R. N. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.11.004 · Cited by 35
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages
Zhao, Z.-W., Zhang, M., Zou, J., Wan, X.-J., Zhou, L., Wu, Y., Liu, S., Liao, L.-X., Li, H., Qin, Y., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.002 · Cited by 34
Ko, J. M. Y., Ning, L., Zhao, X., Chai, A. W. Y., Lei, L. C., Choi, S. S. A., Tao, L., Law, S. Y.-K., Kwong, A., Lee, N. P. Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32619 · Cited by 34
Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene
Cook, E. C. L., Nelson, J. K., Sorrentino, V., Koenis, D., Moeton, M., Scheij, S., Ottenhoff, R., Bleijlevens, B., Loregger, A., & Zelcer, N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172721 · Cited by 31
Wang, W., Zhang, Z., Wu, Y., Wang, R.-Q., Chen, J., Chen, J., Zhang, Y., Chen, Y.-J., Geng, M., Xu, Z., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00459 · Cited by 31
Micah, A. D., Wen, B., Wang, Q., Zhang, Y., Yusuf, A., Thierry, N. N. B., Tokpanou, S. O., Onimisi, M. M., Adeyemi, S. O., Gao, J., et al. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101142 · Cited by 30
A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
Zhao, L., Xuan, Z., Song, W., Zhang, S., Li, Z., Song, G., Zhu, X., Xie, H., Zheng, S., & Song, P. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15881 · Cited by 28
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
HDL in Morbidity and Mortality: A 40+ Year Perspective
Tall, A. R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa148 · Cited by 26
Self-citationWang, X., Lam, S. M., Cao, M., Wang, T., Wang, Z., Yu, M., Li, B., Zhang, H., Ping, F., Song, G., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101855 · Cited by 26
Exploring the Roles of Liver X Receptors in Lipid Metabolism and Immunity in Atherosclerosis
Endo‐Umeda, K., & Makishima, M. (2025) · Biomolecules · doi:10.3390/biom15040579 · Cited by 23
Zhang, C., Lane, L., Omenn, G. S., & Zhang, Y. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00537 · Cited by 22
Lopez, K. A., McDiarmid, C. S., Griffith, S. C., Lovette, I. J., & Hooper, D. M. (2021) · Evolution · doi:10.1111/evo.14243 · Cited by 22
Wang, Z., Pang, J., Wang, L., Dong, Q., & Jin, D. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24703 · Cited by 22
Xia, Y., Xu, Y., Liu, Q., Zhang, J., Zhang, Z., Jia, Q., Tang, Q., Jing, X., Li, J., Chen, J.-H., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155610 · Cited by 21
Barbălată, T., Deleanu, M., Carnuta, M. G., Niculescu, L. S., Răileanu, M., Sima, A. V., & Stancu, C. S. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900029 · Cited by 20
McCabe, K. M., Hsieh, J., Thomas, D. G., Molusky, M. M., Tascau, L., FERANIL, J. B., Qiang, L., Ferrante, A. W., & Tall, A. R. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.010 · Cited by 20
Self-citationILRUN , a Human Plasma Lipid GWAS Locus, Regulates Lipoprotein Metabolism in Mice
Bi, X., Kuwano, T., Lee, P. C., Millar, J. S., Li, L., Shen, Y., Soccio, R. E., Hand, N. J., & Rader, D. J. (2020) · Circulation Research · doi:10.1161/circresaha.120.317175 · Cited by 18
Self-citationWang, M.-Y., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02246-5 · Cited by 18
Mononen, J., Taipale, M., Malinen, M., Velidendla, B., Niskanen, E. A., Levonen, A., Ruotsalainen, A., & Heikkinen, S. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1225 · Cited by 14
Transcriptomic regulatory analysis of skeletal muscle development in landrace pigs
Yu, M., Feng, Y., Yan, J., Zhang, X., Tian, Z., Wang, T., Wang, J., & Shen, W. (2024) · Gene · doi:10.1016/j.gene.2024.148407 · Cited by 13
Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease
Paredes, A. L., Santos-Clemente, R., & Ricote, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157775 · Cited by 13
Wang, T., Yang, C., Peng, L., Li, L., Chen, N., Feng, X., Xie, J., Wu, T., Xu, T., & Chen, Y. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155192 · Cited by 13
Taurine-Mediated IDOL Contributes to Resolution of Streptococcus uberis Infection
Wan, Z., Lan, R., Zhou, Y., Xu, Y., Wang, Z., Luo, Z., & Miao, J. (2021) · Infection and Immunity · doi:10.1128/iai.00788-20 · Cited by 12
TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion
Hsieh, J., Molusky, M. M., McCabe, K. M., Fotakis, P., Xiao, T., Tascau, L., Zeana-Schliep, L., DaSilva-Jardine, P. A., & Tall, A. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.021 · Cited by 12
Self-citationFrancis, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63438-2.00015-8 · Cited by 12
Novel regulators of plasma lipid levels
Loaiza, N., Oldoni, F., & Kuivenhoven, J. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000416 · Cited by 11
Liu, X., Zhang, H., Zhang, K., Deng, X., He, C., Chen, H., Li, G., Zhu, C., & Jiang, M. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.741550 · Cited by 11
Update on lipid species and paediatric nonalcoholic fatty liver disease
Mann, J. P., Feldstein, A. E., & Nobili, V. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000346 · Cited by 10
Structurally Selective Mechanism of Liver X Receptor Ligand: In Silico and In Vitro Studies
Ding, P., Chen, Z., Chen, H., Zhang, Z., Liu, Z., Yan, X., Zhou, H., Gu, Q., Li, C., & Xu, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00292 · Cited by 10
Lei, K., Chen, Y., Wu, J., Lin, Y., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142275 · Cited by 10
A novel seven-gene signature as Prognostic Biomarker in Hepatocellular Carcinoma
Xie, H., Liu, S., Zhang, Z., Chen, P., & Tao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.44573 · Cited by 9
Zhu, W., Huang, P., Li, R., Ran, J., Dai, W., Tang, Y., Lian, P., Ding, C., & Huang, X. (2024) · The FASEB Journal · doi:10.1096/fj.202301748r · Cited by 8
Nogo-B inhibition facilitates cholesterol metabolism to reduce hypercholesterolemia
Xue, C., Zeng, P., Gong, K., Li, Q., Feng, Z., Wang, M., Chen, S., Yang, Y., Li, J., Zhang, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114691 · Cited by 8
Fang, Y., She, J., Zhang, X., Gu, T., Xie, D., Luo, X., Yi, X., Gao, C., Liu, Y., Zhang, C., et al. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c01029 · Cited by 8
Cheng, Y., Xu, H., Cao, W., Gao, W. Z., & Tang, B. (2022) · Journal of the American Ceramic Society · doi:10.1111/jace.18924 · Cited by 8
Li, B., Chang, F., Wan, Z., Giauque, N. A., Addo, E. K., & Bernstein, P. S. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110043 · Cited by 7
Genetics-driven discovery of novel regulators of lipid metabolism
Ha, E. E., Camp, A. G. V., & Bauer, R. C. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000605 · Cited by 7
Hyocholic acid: A novel therapeutic strategy for metabolic syndrome
Rong, B., Zhang, Q., Zhang, X., Zhang, N., Shen, Z., Pang, Y., Lin, X. K., Liu, D., & Yang, X. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100093 · Cited by 5
Zhao, N., Gao, J., Fu, S., & Chen, S. X. (2025) · Aquaculture Reports · doi:10.1016/j.aqrep.2025.102883 · Cited by 5
Yi, X., Li, G., Li, G., Xu, J., Zhang, T., Li, M., Gao, C., Fu, M., Zheng, P., & Chu, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-91319-y · Cited by 4
Yu, X., Zhang, Y., Wu, B., Zhao, B., & Wang, C. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2558654 · Cited by 4
Blanchard, V., & Francis, G. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824048-9.00017-1 · Cited by 4
Maitusong, B., Laguzzi, F., Strawbridge, R. J., Baldassarre, D., Veglia, F., Humphries, S. E., Savonen, K. P., Kurl, S., Pirro, M., Smit, A. J., et al. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003710 · Cited by 4
Huang, J., Yin, R., Li, W., Huang, F., Chen, W., Cao, X., & Chen, Y. (2017) · PubMed Central · Cited by 4
Chiang, C.-P., Huang, Y.-S., Chu, P., Guo, F.-J., Hou, W.-W., Hsu, T., Gong, H., & Huang, C. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.742089 · Cited by 4
Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?
Tran, M., & Wang, L. (2016) · Hepatology · doi:10.1002/hep.28946 · Cited by 4
Jiang, Q. L., Tang, Y.-X., & Zhou, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115457 · Cited by 3
Clostridium butyricum Ameliorates Atherosclerosis by Regulating Host Linoleic Acid Metabolism
Yin, C., Fan, P., Mou, X., & Zhao, W. (2025) · Microorganisms · doi:10.3390/microorganisms13061220 · Cited by 3
Lipoprotein profile and metabolic fine-mapping of genetic lipid risk lociPreprint
Suhre, K., AL-Ishaq, R. K., Belkadi, A., Habib, T., Halama, A., Stephan, N., Thareja, G., Zaghlool, S. B., Fauman, E. B., & Najafi-Shoushtari, S. H. (2022) · medRxiv · doi:10.1101/2022.06.12.22276286 · Cited by 3
Low HDL and High HDL Syndromes
Yamashita, S., & Matsuzawa, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.04000-9 · Cited by 3
Self-citationLiu, M., Hu, J., Chen, Y., Yu, J., Guo, Z., He, S., & Zeng, Y. (2021) · International Journal of Clinical and Experimental Pathology · Cited by 3
Tsui, P.-F., Chern, C., Lien, C., Lin, F., Tsai, C., Tsai, M., & Lin, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114581 · Cited by 3
TTC39B rs1407977 SNP is associated with the risk of coronary heart disease and ischemic stroke.
Li, H., Yin, R., Huang, J., Huang, F., Chen, W., & Cao, X. (2018) · Europe PMC (PubMed Central) · Cited by 2
Deng, X., Liu, X., Pang, L., Gea, R., Chen, H., Li, G., Zhu, C., & Jiang, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-13347-y · Cited by 2
Pang, L., Sheng, D., Wen, S., Fang, L., Jiang, M., Tian, C., Zhou, D., Chen, H., Li, G., & Zhu, C. (2025) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2025.101736 · Cited by 1
Lipid metabolism: from genetic loci to functional understanding
Buerger, F., & Burkhardt, R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000380 · Cited by 1
Kimura, T., & Inoue, I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.15.659736 · Cited by 1
Yang, B., Zhang, B., Cao, Z., Xu, X., Huo, Z., Zhang, P., Xiang, S., Zhao, Z., Lv, C., Meng, M., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0534-z · Cited by 1
Li, Y., Zhang, X., Wu, X., Tan, Y., Lu, N., Jiang, Z., Gao, J., Luo, J., & Wen, X. (2026) · Fishes · doi:10.3390/fishes11010048 · Cited by 1
Effects of LXRα phosphorylation on the regulation of lipid metabolism and hepatic fibrosis
Bécares, N. (2017) · UCL Discovery (University College London)
Nonalcoholic fatty liver disease and cardiovascular disease
Koseki, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817394-7.00011-5
Self-citationYuan, Y., He, D., Deng, M., Ye, Y., Chen, P., Wu, H., Zhang, J., Bao, X., Wang, X., & Zhang, W. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00269-3
Tamehiro, N., Shigemoto‐Mogami, Y., Cui, H., Asakawa, Y., Shibata, N., & Nishimaki‐Mogami, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117304
Miller, C. L., & Leeper, N. J. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.09.006
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639824
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639827
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639830
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639836
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639833
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639815
Wang, M., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16639821
Alan R. Tall: The Downs and (Mostly) Ups of a Life in Science
Ince, S. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.313378
Wang, M.-Y., Liu, F., Fang, B., Huo, Q., & Yang, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-72835/v1
Metadata
- Authors
- Hsieh, J., Koseki, M., Molusky, M. M., Yakushiji, E., Ichi, I., Westerterp, M., Iqbal, J., Chan, R. B., Abramowicz, S., Tascau, L., Takiguchi, S., Yamashita, S., Welch, C. L., Di Paolo, G., Hussain, M. M., Lefkowitch, J. H., Rader, D. J., & Tall, A. R.
- Affiliations
- Columbia University (US)
- Ochanomizu University (JP)
- SUNY Downstate Health Sciences University (US)
- University of Pennsylvania (US)
- The University of Osaka (JP)
- Corresponding author
- Koseki, Masahiro
- Tall, Alan R.
- ORCID
- Venue
- Nature
- Published
- 2016-07
- Volume
- 535
- Issue
- 7611
- Pages
- 303-307
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4947007
- OpenAlex
- W2462155612
- Semantic Scholar
- ee2839ddad345c5575b31795e9c4343879125fb3
- Cited by
- 106
- References
- 38
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 8 · 2022: 6 · 2021: 22 · 2020: 13 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15K16203)
- National Heart, Lung, and Blood Institute (RC2HL101864, R01HL119830, P01HL087123, R01HL111398, HL007343, T32HL007343)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046900, DK-46900, R56DK046900, R29DK046900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- liver X receptor, atherosclerosis, steatohepatitis, non-alcoholic fatty liver disease, HDL cholesterol, ABCA1, ABCG5/8, dietary cholesterol absorption, SREBP1, Western diet
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 5, ATP Binding Cassette Transporter, Subfamily G, Member 8, Liver X Receptors, Animals, Bile Acids and Salts, Cholesterol, Dietary, Fatty Acids, Unsaturated, Fatty Liver, Female, Gene Expression Regulation, Ligands, Lipoproteins, Lipoproteins, HDL, Cholesterol, HDL, Lipoproteins, LDL, Male, Phosphatidylcholines, Receptors, LDL, ATP-Binding Cassette Transporters, Hepatocytes, Lipogenesis, Atherosclerosis, Mice, Sterol Regulatory Element Binding Protein 1, Ubiquitination, Protein Stability, Orphan Nuclear Receptors, Diet, High-Fat, Proteolysis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.